Genentech announces FDA approval of Xofluza (baloxavir marboxil) for influenza
Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration (FDA) has approved Xofluza (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older.